Systematic Reviews
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Jul 15, 2021; 13(7): 732-757
Published online Jul 15, 2021. doi: 10.4251/wjgo.v13.i7.732
Table 5 Long-term and oncologic outcomes
Ref.
Recurrence rate (%)
1-yr OS (%)
3-yr OS (%)
5-yr OS (%)
10-yr OS (%)
1-yr DFS (%)
3-yr DFS (%)
5-yr DFS (%)
1-yr RFS (%)
3-yr RFS (%)
5-yr RFS (%)
LLR in general
Abu Hilal et al[71]16 (after median FU of 22 mo)----------
Allard et al[60]--8570--4231---
Barkhatov et al[25]---54-------
Beard et al[43]---60---44---
Beppu et al[72]-96.384.270.1----70.754.553.4
Berardi et al[73]56.9 (after median FU of 8.4 mo)947454----664637
Castaing et al[32]57 (after median FU of 30 mo)978264-704735653030
Cipriani et al[75]57.785.966.7-----54.229.4-
Cipriani et al[29]-90.876.864.3-68.544.135.860.530.423.7
D’Hondt et al[76]---65-------
de’Angelis et al[44]44.2 (after mean FU of 58.6 ± 44.4 mo)96.180.773.1-7528.821.1---
Eveno et al[78]--7170--3427---
Guerron et al[50]35 (after median FU of 16 mo)----------
Hirokawa et al[79]-1008888-614141---
Iwahashi et al[81]-1008442-571414---
Karagkounis et al[46]--7662-------
Kasai et al[82]-10085.468-55.730.430.4---
Kazaryan et al[26]-846947-634542442424
Kazaryan et al[83]---46-------
Kubota et al[51]--88.4--------
Langella et al[52]37.8 (after median FU of 35.7 ± 24.9 mo)-91.8---69.1----
Lewin et al[84]---54------36
Martínez-Cecilia et al[30]-936843----714331
Nguyen et al[31]-886950-654343---
Postriganova et al[28]-846449-614541483533
Postriganova et al[28]38.5----------
Postriganova et al[28]67.7 (after median FU of 40 mo)92.571.549.3-72.733.522.7---
Postriganova et al[28]-----68.222.718.1---
Tabchouri et al[70]72 (after median FU of 16 mo)-827143------
Tohme et al[55]--74.451.3-------
Vibert et al[87]-9787--7451----
Yue et al[39]52.5 (after FU of 31 mo)--52---45---
Yun et al[88]--95--------
Andorra et al[89]---43.5-------
Major LLR
Nomi et al[57]67.7 (after median FU of 39 mo)----------
Topal et al[58]-90-48-60-43---
Minor LLR
Vavra et al[63]---82.1---63.2---
LLR of posterosuperior segments
Montalti et al[91]-96.470.862.9----63.737.132.5
Okuno et al[42]-100------49.9--
Scuderi et al[93]---------36-
Efanov et al[94]---60-------
Parenchyma sparing LLR
Aghayan et al[47]64 (after median FU of 6 mo)-6848-----3634
Montalti et al[33]57.9 (after mean follow-up of 30.9 mo ± 1.71)987559----64.235.231
Okumura et al[95]59.8 (after median FU of 33.9 mo)-85.1------28.8-
Martínez-Cecilia et al[62]-948265----827154
Simultaneous laparoscopic colorectal and liver resection
Berti et al[40]60 (after median FU of 19 mo)----------
Dagher et al[61]28 (after median FU of 26 mo)9778--7964----
Ferretti et al[64]28.2 (after median FU of 29 mo)98.882.171.9-85.665.963---
Ratti et al[65]36 (after mean FU of 37 mo)----------
Shin et al[34]--74.4---58.5--59.6-
Xu et al[35]--51.3---31.6----
Two-stage hepatectomy
Okumura et al[59]--80--------
Repeat LLR
Nomi et al[36]77.8 (after a median FU of 43 mo)--43.2-------
Hallet et al[37]66.7 (after a median FU of 20.7 mo)---------21.4
DFS: Disease-free survival; FU: Follow-up; LLR: Laparoscopic liver resection; OS: Overall survival; RFS: Recurrence-free survival.